Detalhe da pesquisa
1.
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.
Am J Respir Crit Care Med
; 209(6): 647-669, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38174955
2.
A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients.
J Pharmacokinet Pharmacodyn
; 48(1): 55-67, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949322
3.
Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.
N Engl J Med
; 372(13): 1189-91, 2015 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-25806913
4.
A Trans-Agency Workshop on the Pathophysiology of Radiation-Induced Lung Injury.
Radiat Res
; 197(4): 415-433, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34342637
5.
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Ann Am Thorac Soc
; 14(9): 1395-1402, 2017 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-28388260
6.
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak.
Nat Med
; 14(1): 45-54, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18066075